SG10202010156XA - Compositions and methods for making antibodies based on use of an expression-enhancing locus - Google Patents
Compositions and methods for making antibodies based on use of an expression-enhancing locusInfo
- Publication number
- SG10202010156XA SG10202010156XA SG10202010156XA SG10202010156XA SG10202010156XA SG 10202010156X A SG10202010156X A SG 10202010156XA SG 10202010156X A SG10202010156X A SG 10202010156XA SG 10202010156X A SG10202010156X A SG 10202010156XA SG 10202010156X A SG10202010156X A SG 10202010156XA
- Authority
- SG
- Singapore
- Prior art keywords
- expression
- compositions
- methods
- antibodies based
- making antibodies
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662325385P | 2016-04-20 | 2016-04-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202010156XA true SG10202010156XA (en) | 2020-11-27 |
Family
ID=58701850
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201807881VA SG11201807881VA (en) | 2016-04-20 | 2017-04-20 | Compositions and methods for making antibodies based on use of an expression-enhancing locus |
| SG10202010156XA SG10202010156XA (en) | 2016-04-20 | 2017-04-20 | Compositions and methods for making antibodies based on use of an expression-enhancing locus |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201807881VA SG11201807881VA (en) | 2016-04-20 | 2017-04-20 | Compositions and methods for making antibodies based on use of an expression-enhancing locus |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11530277B2 (es) |
| EP (1) | EP3445780A1 (es) |
| JP (2) | JP7134868B2 (es) |
| KR (2) | KR20180134894A (es) |
| CN (2) | CN116004544A (es) |
| AR (1) | AR108295A1 (es) |
| AU (1) | AU2017253240A1 (es) |
| BR (1) | BR112018071285A2 (es) |
| CA (1) | CA3015371A1 (es) |
| EA (1) | EA201892137A1 (es) |
| IL (2) | IL309065A (es) |
| MX (1) | MX2018012866A (es) |
| SG (2) | SG11201807881VA (es) |
| TW (1) | TW201803981A (es) |
| WO (1) | WO2017184831A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020012591A2 (pt) * | 2017-12-22 | 2020-11-24 | Genentech, Inc. | células hospedeiras de integração direcionada (ti), células hospedeiras ti, métodos para preparar uma célula hospedeira ti, métodos para expressar um polipeptídeo de interesse e vetores |
| WO2020034097A1 (en) | 2018-08-14 | 2020-02-20 | Wuxi Biologics (Shanghai) Co., Ltd. | Transcriptional regulatory element and its use in enhancing the expression of exogenous protein |
| CN112912392A (zh) * | 2018-10-26 | 2021-06-04 | 豪夫迈·罗氏有限公司 | 利用重组酶介导的盒式交换的多特异性抗体筛选方法 |
| CN113631711A (zh) * | 2018-12-21 | 2021-11-09 | 豪夫迈·罗氏有限公司 | 核酸的靶向整合 |
| EP3947437A1 (en) * | 2019-03-29 | 2022-02-09 | F. Hoffmann-La Roche AG | Method for the generation of an fcrn expressing cell by targeted integration of multiple expression cassettes in a defined organization |
| CA3134705A1 (en) | 2019-04-02 | 2020-10-08 | Chugai Seiyaku Kabushiki Kaisha | Method of introducing target-specific foreign gene |
| MX2021015648A (es) | 2019-06-19 | 2022-02-03 | Hoffmann La Roche | Metodo para la generacion de una celula que expresa un anticuerpo multiespecifico multivalente mediante integracion dirigida de multiples casetes de expresion en una organizacion definida. |
| BR112021025425A2 (pt) * | 2019-06-19 | 2022-02-01 | Hoffmann La Roche | Método para produzir uma célula de mamífero recombinante e uso de mrna de recombinase cre |
| AU2020296247A1 (en) * | 2019-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Method for the generation of a trivalent antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization |
| CA3140323A1 (en) | 2019-06-19 | 2020-12-24 | Johannes Auer | Method for the generation of a multivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization |
| BR112021025462A2 (pt) * | 2019-06-19 | 2022-02-01 | Hoffmann La Roche | Métodos para produzir um anticorpo bivalente biespecífico e uma célula de mamífero recombinante, ácido desoxirribonucleico, uso de um ácido desoxirribonucleico, célula de mamífero recombinante e composição |
| WO2023122246A1 (en) * | 2021-12-22 | 2023-06-29 | Genentech, Inc. | Multi-vector recombinase mediated cassette exchange |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US6800457B2 (en) | 1998-09-22 | 2004-10-05 | Bristol-Myers Squibb Company | Expression vectors containing hot spot for increased recombinant protein expression in transfected cells |
| CA2485939C (en) | 2002-05-29 | 2013-10-29 | Regeneron Pharmaceuticals, Inc. | Inducible eukaryotic expression system |
| JP2006512061A (ja) | 2002-11-14 | 2006-04-13 | ジェネンテック・インコーポレーテッド | イントロン融合コンストラクトおよび高発現産生細胞系を選択するための使用方法 |
| WO2006106905A1 (ja) | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | 会合制御によるポリペプチド製造方法 |
| EP1999154B1 (en) | 2006-03-24 | 2012-10-24 | Merck Patent GmbH | Engineered heterodimeric protein domains |
| RS52643B (en) * | 2006-06-02 | 2013-06-28 | Regeneron Pharmaceuticals Inc. | HIGH AFINITY ANTIBODIES TO THE HUMAN IL-6 RECEPTOR |
| EP2115136A4 (en) | 2006-12-21 | 2010-05-19 | Glaxosmithkline Llc | NOVEL PROCEDURE |
| WO2008089396A1 (en) | 2007-01-19 | 2008-07-24 | Invitrogen Corporation | Compositions and methods for genetic manipulation and monitoring of cell lines |
| WO2008119353A1 (en) | 2007-03-29 | 2008-10-09 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| EP2150617B1 (en) | 2007-06-04 | 2014-10-22 | Regeneron Pharmaceuticals, Inc. | Enhanced expression and stability regions |
| WO2009089004A1 (en) | 2008-01-07 | 2009-07-16 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| KR101441437B1 (ko) | 2009-06-02 | 2014-09-25 | 리제너론 파마슈티칼스 인코포레이티드 | 푸코실화-결핍 세포 |
| PL2975051T3 (pl) | 2009-06-26 | 2021-09-20 | Regeneron Pharmaceuticals, Inc. | Wyizolowane z łatwością dwuswoiste przeciwciała o formacie natywnej immunoglobuliny |
| CN104945509A (zh) | 2009-09-16 | 2015-09-30 | 弗·哈夫曼-拉罗切有限公司 | 包含卷曲螺旋和/或系链的蛋白质复合体及其用途 |
| SG184427A1 (en) | 2010-04-20 | 2012-11-29 | Genmab As | Heterodimeric antibody fc-containing proteins and methods for production thereof |
| RU2608640C2 (ru) | 2010-08-16 | 2017-01-23 | Новиммун С.А. | Способы получения мультиспецифичных и мультивалентных антител |
| ES2872081T3 (es) | 2011-08-05 | 2021-11-02 | Regeneron Pharma | Ratones con cadena ligera universal humanizada |
| TWI641687B (zh) | 2012-05-29 | 2018-11-21 | 美商再生元醫藥公司 | 生產細胞株增強子 |
| EP2711428A1 (en) | 2012-09-21 | 2014-03-26 | Lonza Biologics plc. | Site-specific integration |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| TW202206465A (zh) | 2012-11-14 | 2022-02-16 | 美商再生元醫藥公司 | 重組細胞表面捕捉蛋白質 |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| US20140308285A1 (en) | 2013-03-15 | 2014-10-16 | Amgen Inc. | Heterodimeric bispecific antibodies |
| TWI728373B (zh) | 2013-12-23 | 2021-05-21 | 美商建南德克公司 | 抗體及使用方法 |
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| BR112017008022A2 (pt) * | 2014-10-23 | 2018-02-20 | Regeneron Pharmaceuticals, Inc. | célula, polinucleotídeo, veículo, e, métodos para modificação de um genoma de células cho e para preparação de uma proteína de interesse. |
| MD3353212T2 (ro) | 2015-09-23 | 2022-03-31 | Regeneron Pharma | Anticorpi bispecifici anti-CD3 optimizați și utilizările acestora |
-
2017
- 2017-04-20 KR KR1020187029371A patent/KR20180134894A/ko not_active Application Discontinuation
- 2017-04-20 US US16/095,067 patent/US11530277B2/en active Active
- 2017-04-20 EA EA201892137A patent/EA201892137A1/ru unknown
- 2017-04-20 BR BR112018071285A patent/BR112018071285A2/pt not_active Application Discontinuation
- 2017-04-20 IL IL309065A patent/IL309065A/en unknown
- 2017-04-20 AR ARP170101018A patent/AR108295A1/es unknown
- 2017-04-20 KR KR1020217035334A patent/KR102474757B1/ko not_active Application Discontinuation
- 2017-04-20 CN CN202211344339.4A patent/CN116004544A/zh active Pending
- 2017-04-20 IL IL262268A patent/IL262268B1/en unknown
- 2017-04-20 TW TW106113300A patent/TW201803981A/zh unknown
- 2017-04-20 AU AU2017253240A patent/AU2017253240A1/en active Pending
- 2017-04-20 CN CN201780024560.2A patent/CN109071633B/zh active Active
- 2017-04-20 MX MX2018012866A patent/MX2018012866A/es unknown
- 2017-04-20 EP EP17723182.6A patent/EP3445780A1/en active Pending
- 2017-04-20 JP JP2018552822A patent/JP7134868B2/ja active Active
- 2017-04-20 SG SG11201807881VA patent/SG11201807881VA/en unknown
- 2017-04-20 WO PCT/US2017/028552 patent/WO2017184831A1/en active Application Filing
- 2017-04-20 CA CA3015371A patent/CA3015371A1/en active Pending
- 2017-04-20 SG SG10202010156XA patent/SG10202010156XA/en unknown
-
2022
- 2022-08-31 JP JP2022137796A patent/JP2022164824A/ja active Pending
- 2022-11-10 US US18/054,350 patent/US20230322956A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3445780A1 (en) | 2019-02-27 |
| BR112018071285A2 (pt) | 2019-02-12 |
| US11530277B2 (en) | 2022-12-20 |
| IL262268B1 (en) | 2024-01-01 |
| EA201892137A1 (ru) | 2019-03-29 |
| CA3015371A1 (en) | 2017-10-26 |
| US20230322956A1 (en) | 2023-10-12 |
| KR102474757B1 (ko) | 2022-12-07 |
| TW201803981A (zh) | 2018-02-01 |
| IL309065A (en) | 2024-02-01 |
| SG11201807881VA (en) | 2018-10-30 |
| AU2017253240A1 (en) | 2018-09-20 |
| CN116004544A (zh) | 2023-04-25 |
| MX2018012866A (es) | 2019-03-11 |
| WO2017184831A1 (en) | 2017-10-26 |
| AR108295A1 (es) | 2018-08-08 |
| JP2022164824A (ja) | 2022-10-27 |
| CN109071633B (zh) | 2022-11-18 |
| KR20180134894A (ko) | 2018-12-19 |
| JP2019514358A (ja) | 2019-06-06 |
| KR20210135340A (ko) | 2021-11-12 |
| IL262268A (en) | 2018-11-29 |
| US20190263937A1 (en) | 2019-08-29 |
| JP7134868B2 (ja) | 2022-09-12 |
| CN109071633A (zh) | 2018-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL262268A (en) | Preparations and methods for the preparation of antibodies based on the use of an amplified expression locus | |
| IL291711A (en) | Anti-ctla-4 antibodies and methods of using them | |
| EP3515478A4 (en) | ANTIBODIES FOR SIGLEC-15 AND METHODS OF USING SAME | |
| IL265800A (en) | Anti-lag-3 antibodies and methods of using them | |
| IL266918A (en) | Anti-ctla-4 antibodies and methods of using them | |
| SG10201912879YA (en) | Anti-sirp-alpha antibodies and methods of use thereof | |
| IL262266A (en) | Preparations and methods for preparing antibodies based on the use of expression enhancer loci | |
| EP3383430A4 (en) | ANTIBODIES AND METHOD FOR USE THEREOF | |
| SG10201912563XA (en) | Anti-tim-3 antibodies and methods of use thereof | |
| EP3280441A4 (en) | Anti-sortilin antibodies and methods of use thereof | |
| EP3105335A4 (en) | Chimeric antigen receptors and methods of making | |
| EP3316909A4 (en) | ANTI-NTB-A ANTIBODIES AND ASSOCIATED COMPOSITIONS AND METHODS | |
| EP3383917A4 (en) | NOVEL ANTI-CLAUDIN ANTIBODIES AND METHODS OF USE | |
| IL265438A (en) | Chimeric antigen receptors and jewelry and methods of using them | |
| EP3559042A4 (en) | ANTI-LILRB3 ANTIBODIES AND METHOD OF USING THEREOF | |
| EP3218370A4 (en) | Methods and compositions for inhibition of bromodomain and extraterminal proteins | |
| IL265957A (en) | Anti-c1s antibodies and methods of using them | |
| EP3443076A4 (en) | COMPOSITIONS AND METHODS FOR CHIMERAL ALLOANTigen RECEPTOR T CELLS | |
| EP3313993A4 (en) | ANTI-APOBEC3 ANTIBODIES AND METHOD OF PREPARATION AND USE | |
| EP3538153A4 (en) | ANTI-CD46 ANTIBODIES AND METHOD FOR USE | |
| EP3365367A4 (en) | MONOCLONAL ANTIBODIES TO BED TAILS AND METHOD FOR THE PRODUCTION AND USE THEREOF | |
| EP3319930A4 (en) | METHOD AND COMPOSITIONS FOR STABILIZING PROTEINS | |
| EP3454864A4 (en) | NOVEL ANTI-BMPR1B ANTIBODIES AND METHOD OF USING | |
| AU2015901092A0 (en) | PAT-SM3 related antibodies and methods of making and using same | |
| AU2014901301A0 (en) | PAT-SM3 related antibodies and methods of making and using same |